Astemizole: a long-acting, nonsedating antihistamine

Area of Science:

• Pharmacology
• Allergy and Immunology

Background:

• Histamine H1-receptor antagonists are crucial for managing allergic conditions.
• Conventional antihistamines often cause significant sedation and anticholinergic side effects.
• There is a need for effective antihistamines with improved safety profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of astemizole as a histamine H1-receptor antagonist.
• To compare astemizole with existing treatments for allergic rhinitis and urticaria.
• To assess astemizole's suitability for chronic allergic condition management.

Main Methods:

• Review of comparative studies and clinical data on astemizole.
• Analysis of astemizole's pharmacokinetic properties, including half-life and metabolite activity.
• Assessment of reported efficacy in allergic rhinitis, conjunctivitis, and chronic urticaria.

Main Results:

• Astemizole demonstrates efficacy comparable or superior to existing antihistamines, beclomethasone nasal spray, and cromolyn sodium for seasonal and perennial allergic rhinitis.
• It is also effective for allergic conjunctivitis and chronic urticaria.
• Astemizole has a delayed onset of action, making it less suitable for acute allergic symptoms.
• Lower incidence of sedation compared to conventional antihistamines, though increased appetite and weight gain are noted.
• Long elimination half-lives of astemizole and its metabolite allow for once-daily dosing.

Conclusions:

• Astemizole is a valuable option for maintenance and prophylactic therapy in chronic allergic conditions.
• It is particularly beneficial for patients intolerant to sedative or anticholinergic effects of conventional antihistamines.
• Its long-acting profile and reduced sedation enhance patient compliance and quality of life.